XERS News and Press, Xeris Pharmaceuticals Inc. From 05/24/21

Xeris Pharmaceuticals (XERS) will acquire Strongbridge Biopharma (SBBP) for stock and contingent value rights (CVRs) transaction.The agreement, including the maximum amount payable under the CVRs, values Strongbridge at ~$267M.The deal is expected to close early in Q4 2021.Upon closing, ...

Xeris Pharmaceuticals recently reported their Q1 earnings with a slight beat on EPS and revenue. Unfortunately, Xeris reported in the middle of the healthcare sell-off and XERS was unjustly punished. The company's flagship product, Gvoke, continues to report impressive commercial...

Xeris Pharmaceuticals, Inc. (XERS) Q1 2021 Earnings Conference Call May 13, 2021, 8:30 AM ET Company Participants Allison Wey - Senior Vice President, Investor Relations and Corporate Communications Paul Edick - Chairman and CEO Barry Deutsch - Chief Financial Officer Conference Call Particip...

Xeris Pharmaceuticals (XERS): Q1 GAAP EPS of -$0.30 beats by $0.06.Revenue of $8.05M (+379.2% Y/Y) beats by $0.56M. As of March 31, 2021, Xeris reported total cash, cash equivalents, and investments of $135.9 million, compared to $133.8 million at December 31, 2020.Shares -1.5% PM.Press ...

Gvoke® quarterly net sales of $8.1 million R ecord quarterly Gvoke prescription volume Strong cash position of $136.0 million Conference call and webcast today at 8:30 a.m. ET Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceut...

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceut...

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the Company will release its first quarter 2021...

Provides up to 12 months of interest-only payments to January 2023 upon achievement of certain revenue targets Delays up to $17.4 million of principal payments Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formula...

Gainers: [[LAUR]] +14.2%. [[TEAM]] +7.5%. [[FIVN]] +7.3%. [[TXRH]] +6.1%. [[XERS]] +5.7%.Losers: [[ARDX]] -16.8%. [[MVIS]] -16.8%. [[SWKS]] -7.3%. [[MRKR]] -5.6%. [[LLNW]] -4.9%. For further details see: SWKS, TEAM, MVIS and FIVN among after-hours movers

Xeris Pharmaceuticals (XERS) announces that the United Kingdom’s Medicines and Healthcare Regulatory Agency ((MHRA)) has approved Ogluo (glucagon) injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.The m...